FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer

FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer

Background and objective Lung cancer is the malignant tumor with the highest incidence and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for about 80%. Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted therapy has been playing an important r...

Full description

Bibliographic Details
Main Authors: Cong PENG, Pan LI, Mingqiang YANG, Danyang CHEN, Yuanfeng HUANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-08-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
foxc1
gefitinib resistance
cancer stem cells
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2021.103.11

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2021.103.11

Similar Items